{"id":4990,"date":"2026-04-01T13:29:43","date_gmt":"2026-04-01T03:29:43","guid":{"rendered":"\/eu-uk\/?p=4990"},"modified":"2026-04-01T15:34:28","modified_gmt":"2026-04-01T05:34:28","slug":"investor-presentations-march-2026","status":"publish","type":"post","link":"\/eu-uk\/blog\/2026\/04\/01\/investor-presentations-march-2026\/","title":{"rendered":"Investor Presentations | March 2026"},"content":{"rendered":"<h2><b><span data-contrast=\"auto\">Expanding US momentum\u00a0and commercial progress for\u00a0Remplir\u2122<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/h2>\n<p><span data-contrast=\"auto\">Orthocell<\/span><span data-contrast=\"auto\">\u00a0CEO and MD,\u00a0<\/span><span data-contrast=\"auto\">P<\/span><span data-contrast=\"auto\">aul<\/span><span data-contrast=\"auto\">\u00a0Anderson, presented at\u00a0<\/span><span data-contrast=\"auto\">two investor-facing events on 31 March 2026, providing an in-depth update on the\u00a0Company\u2019s commercial progress and global\u00a0expansion strategy.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"auto\">Ausbiz<\/span><\/b><b><span data-contrast=\"auto\">\u00a0Capital Investor Connect\u00a0<\/span><\/b><\/h3>\n<p><span data-contrast=\"auto\">Presenting to a broad investor audience at the\u00a0Ausbiz\u00a0Capital\u00a0<\/span><span data-contrast=\"auto\">Investor Connect Biotech &amp; Pharmaceuticals Special, the presentation focused on the scale of the US opportunity for Orthocell and the early execution of the Company\u2019s commercial strategy. <\/span><span data-ccp-props=\"{}\">\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Paul\u00a0emphasised\u00a0the sheer size of the US peripheral nerve market,\u00a0with more than 700,000 procedures performed annually\u00a0in the United States, the majority of which still rely on traditional suturing techniques. He also\u00a0noted\u00a0that\u00a0the Company could achieve cash\u00a0breakeven\u00a0with only 5,000-\u00a06,000\u00a0procedures per year\u00a0\u2013\u00a0representing\u00a0less that 1% of the addressable market.\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">He also highlighted the growth in surgeon adoption of\u00a0Remplir\u2122,\u00a0describing the product as addressing a clear unmet need in surgical practice:<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"auto\">\u201cSurgeons\u00a0<\/span><\/i><i><span data-contrast=\"auto\">are liking<\/span><\/i><i><span data-contrast=\"auto\">\u00a0what\u00a0<\/span><\/i><i><span data-contrast=\"auto\">they\u2019re<\/span><\/i><i><span data-contrast=\"auto\">\u00a0feeling.\u00a0<\/span><\/i><i><span data-contrast=\"auto\">They\u2019re liking<\/span><\/i><i><span data-contrast=\"auto\">\u00a0the way that it works in theatre for them. [As a result]\u00a0<\/span><\/i><i><span data-contrast=\"auto\">we\u2019re<\/span><\/i><i><span data-contrast=\"auto\">\u00a0seeing both directed growth and organic growth, which is a great sign of a fantastic product. From a unit sales perspective,\u00a0<\/span><\/i><i><span data-contrast=\"auto\">we\u2019ve<\/span><\/i><i><span data-contrast=\"auto\">\u00a0also seen a significant increase \u2014 from one patient in June to between 110\u2013120 patients in the last quarter.\u201d<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><iframe loading=\"lazy\" title=\"Replay | Ausbiz Capital Investor Connect Presentation\" width=\"1180\" height=\"664\" src=\"https:\/\/www.youtube.com\/embed\/KPjsBCjL4XY?feature=oembed&#038;enablejsapi=1&#038;origin=https:\/\/orthocell.com\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<h3><b><span data-contrast=\"auto\">Broker Meets Biotech, Perth<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"auto\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5317 alignleft\" src=\"\/wp-content\/uploads\/2026\/04\/WhatsApp-Image-2026-04-01-at-11.32.34-650x433.jpeg\" alt=\"\" width=\"552\" height=\"367\" \/>In the afternoon, Paul presented to brokers and investors in Perth,\u00a0providing\u00a0a more detailed view of\u00a0Orthocell\u2019s\u00a0commercial performance and growth\u00a0trajectory. The\u00a0session\u00a0expanded\u00a0on the early traction outlined in the\u00a0Ausbiz\u00a0presentation, with data\u00a0demonstrating\u00a0rapid uptake since\u00a0launch.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><strong>Key highlights\u00a0include:\u00a0<\/strong><\/p>\n<ul>\n<li><span data-contrast=\"auto\">Surgeon numbers increased from 1\u00a0to 48 in 9 months<\/span><\/li>\n<li><span data-contrast=\"auto\">Hospitals expanded to 52 sites since first sale<\/span><\/li>\n<li>Quarterly unit sales grew to over 110-120 units<\/li>\n<\/ul>\n<p>Paul then compared that growth over a few quarters with the Australia &amp; New Zealand market growth and how we plan to replicate that in the US market.<\/p>\n<p><span data-contrast=\"auto\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5319 alignnone\" src=\"\/wp-content\/uploads\/2026\/04\/2603_OCC_Investor-Presentation_Ausbiz_V03-15-e1775004546514.jpg\" alt=\"\" width=\"467\" height=\"263\" \/><\/span><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5320 alignnone\" src=\"\/wp-content\/uploads\/2026\/04\/2603_OCC_Investor-Presentation_Ausbiz_V03-16.jpg\" alt=\"\" width=\"500\" height=\"281\" \/><\/p>\n<p><span data-contrast=\"auto\">Paul also provided further clarity on the Company&#8217;s pathway to profitability, reiterating that breakeven can be achieved at approximately 5,000\u20136,000 procedures annually, supported by a relatively modest base of active surgeons. This target is considered achievable based on current pipeline activity and prior experience in Australia, where the Company has already demonstrated strong adoption across hundreds of surgeons and hospitals.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The presentation also\u00a0highlighted emerging opportunities to expand the use of\u00a0Remplir\u2122 into prostate cancer surgery, where the product is being used to support nerve preservation and improve post-operative functional outcomes.\u00a0\u00a0This expansion has the potential to meaningfully increase the total addressable market for\u00a0Remplir\u2122, reinforcing the broader growth profile of the platform.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><a href=\"\/eu-uk\/wp-content\/uploads\/sites\/6\/2026\/04\/2603_OCC_Investor-Presentation_Broker-meets-Biotech.pdf\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"auto\">Download the Investor Presentation<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on the Company\u2019s commercial progress and global expansion strategy.  <\/p>\n","protected":false},"author":2,"featured_media":4991,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2,1],"tags":[],"class_list":["post-4990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-video"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4990"}],"version-history":[{"count":2,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4990\/revisions"}],"predecessor-version":[{"id":4996,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4990\/revisions\/4996"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4991"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4990"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}